Search
Displaying 581–590 of 898 results for “vision connection”
-
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Beacon Stories
Maverick, a determined and adventurous 11-year-old, was diagnosed with X-linked retinoschisis (XLRS) at age six, which led his family to find support and resources through the Foundation Fighting Blindness. Since his diagnosis, Mav continues to pursue his passions in sports and outdoor activities, inspiring his family with his resilience and positive attitude.
-
From its legendary cowboy culture to world-class art, lush outdoor escapes, and a vibrant food scene, Fort Worth offers something for everyone. Whether you’re exploring the iconic Stockyards, strolling through the Cultural District, or enjoying the city’s lively neighborhoods, you’ll find plenty of ways to make the most of your visit during United in Vision 2026.
-
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
Research NewsThe Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
About Page
The Foundation Fighting Blindness Brand Ambassador Program empowers passionate individuals affected by blinding diseases to share their stories, raise awareness, and inspire action in the fight against vision loss. Together, we’re amplifying voices and accelerating our path to treatments and cures.
